ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
February 15, 2024 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
July 26, 2023 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)
April 10, 2023 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, April 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
February 23, 2023 16:16 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
January 05, 2023 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval
November 17, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...